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Abstract
Introduction:  Cranial nerve neuropathy is a rare presentation of advanced cancer of the prostate.
Observation:  We report a case of 65-year-old man who presented with right lower motor neuron (LMN)
facial nerve palsy. The prostate had malignant features on digital rectal examination (DRE) and the prostate
specific antigen (PSA) was 116 ng/ml. Histology of the prostate biopsy confirmed an adenocarcinoma with
the Gleason score of (4 + 3) = 7/10. The computerised tomography (CT) scan of the skull revealed dense
osteosclerosis at the base, worse in the petrous part of the right temporal bone with narrowed ipsilateral facial
nerve canal. Androgen deprivation therapy (ADT) was achieved by bilateral orchidectomy. Analgesics and
bisphosphonates with facial muscles physiotherapy were also administered. He had significant resolution
of the facial nerve palsy and the other symptoms at subsequent follow-ups. The related literatures were
reviewed.
Conclusion:  Facial nerve palsy as a primary presentation of advanced cancer of the prostate is unusual, is re
urgeons’ Association. Production and hosting by Elsevier B.V. All rights reserved.thus, a high index of suspicion
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quality of life [13], it was expedient to establish the cause. Metas-
tasis to the temporal bone typically presents with the classical triad
of otalgia, periauricular swelling and facial nerve palsy [14] but this
patient had only facial nerve palsy.Facial nerve palsy as a primary presentation of advanced carcinoma
Introduction
Cranial nerves may be invaded by malignant tumour from Cranio-
oropharyngeal region or rarely the metastasis from distal sites such
as the breast, lung, prostate and kidney following the haematoge-
nous spread to the base of the skull [1]. The few reported cases of
cranial nerve palsies from metastatic prostate cancer were however
in patients whose disease progressed while on palliative treatment.
These resulted in recognised syndromic cranial nerve lesions such
as Villaret’s syndrome [2], Occipital condyle syndrome [3], Jugular
foramen syndrome [4], Parasellar syndrome [5], Collet syndrome
[6] or isolated II [7], III, VI and VIII nerves palsy [8,9]. Isolated
facial nerve palsy is unusual as the first presentation of the patient
with advanced carcinoma of the prostate.
We obtained a written consent from the patient, and clearance from
the Hospital Ethics Committee to report this unusual presentation
of an advanced prostate cancer.
Case  report
A 65-year-old man, retired journalist, who presented with three
weeks history of deviation of his mouth towards the left side and
difficulty with feeding due to the escape of feeds from the contra
lateral angle of his mouth. He could not close the right eye even
while asleep. On further evaluation, he was found to have mild irri-
tative lower urinary tract symptoms (LUTS), low back pain that
was not bothersome and generalised body weakness. He was not
hypertensive or diabetic and had no other co-morbidity.
On physical examination, he was pale, had lost the naso-labial fold
on the right side of the face while his mouth was deviated to the
left. His right eye remained opened on his attempt to clench his
teeth and close his eyes (Fig. 1). He had no swelling in the peri-
auricular region and his ear, nose and throat (ENT) examinations
were normal. The rectal examination revealed an enlarged prostate
with malignant features; clinical stage T2C. His Pack Cell Volume
was 25% and hence, he was transfused two units of whole blood. The
PSA was 116 ng/ml and the six cores of the digital guided prostate
biopsy taken all confirmed adenocarcinoma of the prostate that had
the Gleason score of 7/10(4 + 3) (Fig. 2). His lumbosacral radio-
graphs revealed osteoblastic bone lesions involving the lumbosacral
and pelvic bones. The skull CT showed dense sclerosis at the base
which was worse in the petrous part of the right temporal bone with
narrowed ipsilateral facial nerve canal (Figs. 3 and 4) but the cere-
bral and cerebellar hemispheres were normal. He was counselled
for palliative treatment. Androgen deprivation therapy was achieved
by bilateral orchidectomy. Other adjuvant treatments he had were;
facial muscles physiotherapy, analgesics and oral bisphosphonates.
He had significant resolution of symptoms at subsequent follow ups;
he had regained good facial symmetry with the reappearance of the
nasolabial fold on the right side and he could close both eyes (Fig. 5).
Discussion
Prostate cancer is the second commonest malignancy in men world-
wide [10]; however, it accounts for only 6% of the metastasis from
all cancers to the skull [11]. The exact mechanisms of its haematoge-
nous spread to the skull is still poorly understood [12]. Only a
few cases of facial nerve palsy following metastasis from prostate
cancer to the base of the skull in patients with castration resistant
F
Higure  1  Right eye remained open on attempt at closing the eyes and
lenching the teeth seen in right LMN facial nerve palsy.
rostate cancer (CRPC) have been reported in the literature. We
ould not find any report of facial nerve palsy as the first sole
resentation of cancer of the prostate prior to ADT or before the
evelopment of CRPC. Our patient presented primarily with facial
erve palsy, which posed a significant diagnostic challenge. Because
f the impact of facial nerve palsy on the patient’s body image andigure  2  Histology of the patient’s prostate biopsy specimen.
aematoxylin  and  Eosin  Stain (40×). Gleason score (4 + 3) = 7/10.
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Figure  3  Lateral scanogram, showing numerous miliary lytic lesions
involving the entire calvarium. The skull base showed sclerosis, espe-
cially at the level of the middle cranial fossa (arrow).
Figure  4  Axial section of non-contrast CT scan at the level of the
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Figure  5  Third month at follow up – good facial symmetry, regained
r
P
a
T
l
n
t
i
d
r
T
A
t
g
o
i
r
p
p
t
(
C
L
p
suspicion. The patient’s age, DRE findings, PSA and radiologic
investigations should raise the suspicion of prostate cancer. ADTase of the skull, showing narrowed right facial nerve canal
he patient had no other lesion that could explain his facial nerve
alsy. The common causes, which includes; infective, metabolic,
raumatic, toxins and loco regional lesions [15] were all ruled out in
he patient. The preceding LUTS and low back pain were mild and
ot bothersome, and thus he did not seek for their treatment in any
ealth facility. Delayed presentation is common in our environment
ecause of the poor health seeking behaviour and ignorance. Hence,
ost patients with prostate cancer are often seen for the first time
ith an advanced disease [16,17]. The digital rectal examinationDRE) has only 27.1% and 49% sensitivity and specificity respec-
ively; while the use of PSA alone for screening has a sensitivity
f 34.9% and specificity of 63.1%. The combination of DRE with
i
p
might nasolabial fold and he could now close both eyes
SA significantly improves prostate cancer detection (sensitivity
nd specificity of 38.0 and 87.9% respectively) [18].
he CT findings in our patient revealed predominantly osteolytic
esion at calvarium and osteosclerosis at the base of the skull with
arrowed facial nerve canal on the right side. The petrous part of
he temporal bone is the part of the base the skull predominantly
nvolved in patients with facial nerve palsy resulting from secon-
aries [1,19], in our patient the sclerotic lesion is worse in that
egion.
he treatment for prostate cancer generally is on a case to case basis.
ndrogen deprivation therapy remains the gold  standard palliative
reatment for the advance prostate  cancer, thus this patient had sur-
ical castration (bilateral Orchidectomy). He was also treated with
ral bisphosphonates in the form of weekly alendronate  shown to
ncreased bone mineral density and decreased the risk of skeletal
elated events in patients with prostate cancer on ADT [20]. Our
atient might have benefitted from radiotherapy  to the right tem-
oral region, however, the response to ADT was remarkable and
here was marked and sustained improvement in facial nerve palsy
Fig. 5), LUTS and the low back pain over the period of follow up.
onclusion
MN facial nerve palsy is an unusual presentation of advanced
rostate cancer. Therefore, the diagnosis requires a high index ofs an effective palliative treatment as is the case in most advanced
rostate cancer. Adjuvant treatment with bisphosphonates and facial
uscles physiotherapy appeared to be beneficial.
 of th
[
[
[
[
[
[
[
[
[
[
[Facial nerve palsy as a primary presentation of advanced carcinoma
Ethical  committee  approval
This study obtained the approval of the ethical committee.
Author’s  contribution
A. Abubakar: The concepts and study design with coordination
of co-authors contributions. Acquisition of data and analysis (aab-
dulkadir21@gmail.com).
M. Ahmed: The analysis, interpretation of the case concept and
design (darm313@yahoo.com).
M. Tela: Acquisition of data and drafting the article, concept and
design (umtela@yahoo.com).
A. Ismail: Substantial contributions in interpretation with the analy-
sis of the appropriate investigations done by the patient particularly
the computer tomography including labelling and contributions in
the study concepts (ibnmalikanas@yahoo.co.uk).
M. Abubakar: Revising the study critically for important
intellectual content, contributed to the design and concept
(bgmustapha2003@yahoo.co.uk).
Conflict  of  interests
Nil.
Source  of  funding
Nil.
References
[1] Streitmann M, Sismanis A. Metastatic carcinoma of the temporal bone.
Am J Otol 1996;17:780–3.
[2] Sicenica T, VenkataBalaji G, Klein A, Berman P, Ahmad U. Vil-
laret’s syndrome in a man with prostate carcinoma. Am J Med
2000;108:516–7.[3] Capobianco DJ, Brazis PW, Rubino FA, Dalton JN. Occipital condyle
syndrome. Headache 2002;42:142–6.
[4] Wilson H, Johnson DH. Jugular foramen syndrome as a complication
of metastatic cancer of the prostate. South Med J 1984;77:92–3.e prostate 23
[5] Ransom DT, Dinapoli RP, Richardson RL. Cranial nerve lesions
due to base of the skull metastases in prostate carcinoma. Cancer
1990;65:586–9.
[6] Prashant R, Franks A. Collet-Sicard syndrome—a report and review.
Lancet Oncol 2003;4:376–7.
[7] Kattah JC, Chrousos GC, Roberts J, Kolsky M, Zimmerman L, Manz
H. Metastatic prostate cancer to the optic canal. Ophthalmology
1993;100:1711–5.
[8] McAvoy CE, Kamalarajab S, Best R, Rankin S, Bryars J, Nelson K.
Bilateral third and unilateral sixth nerve palsies as early presenting signs
of metastatic prostatic carcinoma. Eye 2002;16:749–53.
[9] Seymore CH, Peeples WJ. Cranial nerve involvement with carcinoma
of prostate. Urology 1988;31:211–3.
10] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo
M, et al. Cancer incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012. Int J Cancer
2015;136(5):E359–86.
11] Mitsuya K, Nakasu Y, Horiguchi S, Harada H, Nishimura T, Yuen S,
et al. Metastatic skull tumours: MRI features and conventional classi-
fications. J Neurooncol 2010 Nov 26.
12] Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky
VV. Mechanical entrapment is insufficient and intercellular adhesion is
essential for metastatic cell. Arrest in distant organs. Neoplasia (New
York, NY) 2005;7(5):522–7.
13] Fu L, Bundy C, Sadiq SA. Psychological distress in people with dis-
figurement from facial palsy. Eye (Lond) 2011;25(10):1322–6.
14] Maddox HE. Metastatic tumors of the temporal bone. Ann Oto Rhinol
Larygol 1967;76:149–65.
15] Causes of facial paralysis (n.d.). The New York eye and ear infirmary.
Retrieved July 19, 2012, from http://www.nyee.edu/facialparalysis-
causes.htm.
16] Dawam D, Rafindadi AH, Kalayi GD. Benign prostatic hyperplasia and
prostate carcinoma in native Africans. BJU Int 2000;85:1074–7.
17] Ndubuisi SC, kofie VY, Andoh JY, Schwartz FM. Black–white differ-
ences in the stage at presentation of prostate cancer in the District of
Columbia. Urology 1995;46:71–7.
18] Parpart S, Rudis A, Schreck A, Dewan N, Warren P. Sensitivity and
specificity in prostate cancer screening methods and strategies. J Young
Invest 2007.
19] Gloria-Cruz TI, Schachern PA, Paparella MM, Adams GL, Fulton SE.
Metastases to temporal bones from primary nonsystemic malignant
neoplasms. Arch Otolaryngol Head Neck Surg 2000;126:209–14.
20] Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian
Urology Research Consortium. A phase 3, double-blind, randomised,
parallel-group, placebo-controlled study of oral weekly alendronate
for the prevention of androgen deprivation bone loss in nonmetastatic
prostate cancer: the Cancer and Osteoporosis Research with Alen-
dronate and Leuprolide (CORAL) study. Eur Urol 2013;63(5):927–35.
